GREER® Laboratories, Inc. Completes Deal with Ares Life Sciences
News May 01, 2013
“We are pleased that this transaction has been finalized, and we renew our commitment to allergy immunotherapy, our customers and their patients, ensuring that we will continue to deliver quality allergy immunotherapy products, services and customer support,” shares John G. Roby, GREER President and CEO.
GREER’s clinical development programs are focused on the company’s investigational sublingual allergy immunotherapy liquid (SAIL™). The company recently completed a successful Phase III study evaluating the efficacy and safety of GREER® SAIL™ as a treatment for adults with short ragweed allergies. Sublingual allergy immunotherapy (SLIT) is a method of allergy immunotherapy that delivers the same liquid allergenic extract approved for subcutaneous injections, but it is administered under the tongue. SLIT has been widely accepted as a safe, effective treatment for allergic rhinitis in Europe for years.1 However, SLIT is currently investigational in the United States.
Drug May Suppress Deadly Immune Response When Trauma Spills the Contents of Cell PowerhousesNews
When trauma spills the contents of our cell powerhouses, it can evoke a potentially deadly immune response much like a severe bacterial infection. A drug that cleaves escaped proteins called N-formyl peptides appears to reduce resulting dangerous leakage from blood vessels and improve survival.READ MORE
Treg Cells Protect Babies from Getting HIV Infection from their MothersNews
Treg cells, a type of regulatory lymphocyte, may be protecting babies in the womb from getting infected with the HIV virus when the mother is infected.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018